Alan Wise (L) and Peter Trill (Duke Street Bio)

They sold their last biotech to Mer­ck. Now they're back with a PARP out­fit named af­ter a Lon­don street

In 2016, Pe­ter Trill and Alan Wise sold IOmet Phar­ma (an I/O out­fit as the name sug­gests) to Mer­ck for $400 mil­lion.

Now, some six years lat­er, the duo has re­turned with an­oth­er can­cer biotech, Duke Street Bio, that emerged from stealth Tues­day. Duke Street Bio, named for the street where it’s lo­cat­ed in Lon­don, is mak­ing its pub­lic de­but as a next-gen PARP play­er, hop­ing to break in­to a field that al­ready has a num­ber of Big Phar­ma com­peti­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.